Baxion
Screening
Tags
Alerts
Theme
Engene Therapeutics Inc.
ENGN
·
NASDAQ
·
$1.76
Share Price as of 11/2
·
$90M
Market Cap as of 11/2
Categorized
Chronological
Ownership
Credit
Contracts
Plans
Incorporation
Transcripts
Tags
Financials
Filter
10-Q
Quarterly Report
09/08/26
10-Q
Q2 ended 04/30/26
06/15/26
10-Q
Q1 ended 01/31/26
03/09/26
10-K/A
FY 2025
02/19/26
10-K
FY 2025
12/22/25
Disclosures
Filter
8-K
Results of Operations
09/08/26
8-K
Current report
08/11/26
8-K
Regulation FD Disclosure
07/17/26
8-K
Current report
07/16/26
8-K/A
Exit or Disposal Activities; Change in Directors or Officers
06/18/26
Prospectuses and Registrations
Filter
424B5
Prospectus supplement
03/09/26
S-8
Registration of securities for employees
03/09/26
S-3
Shelf registration
02/19/26
424B5
Prospectus supplement
11/14/25
424B5
Prospectus supplement
11/12/25
Proxies
Filter
DEF 14A
Definitive proxy
05/08/26
DEF 14A
Definitive proxy
05/09/25
DEF 14A
Definitive proxy
04/18/24
Ownership
Filter
Form 4
Insider transaction
09/24/26
SC 13G/A
Beneficial ownership (amended)
08/14/26
SC 13G/A
Beneficial ownership (amended)
08/14/26
SC 13G/A
Beneficial ownership (amended)
08/14/26
SC 13G/A
Beneficial ownership (amended)
08/13/26
Other
Filter
ARS
Annual report to shareholders
05/08/26
EFFECT
Request for effectiveness
03/02/26
CORRESP
Correspondence with the SEC
02/26/26
UPLOAD
Letter from the SEC
02/25/26
ARS
Annual report to shareholders
05/09/25
Latest Filings
Filter
10-Q
Quarterly Report
09/08/26
8-K
Results of Operations
09/08/26
8-K
Current report
08/11/26
8-K
Regulation FD Disclosure
07/17/26
8-K
Current report
07/16/26
Ownership
Filter
Form 4
Insider transaction
09/24/26
SC 13G/A
Beneficial ownership (amended)
08/14/26
SC 13G/A
Beneficial ownership (amended)
08/14/26
SC 13G/A
Beneficial ownership (amended)
08/14/26
SC 13G/A
Beneficial ownership (amended)
08/13/26